<p>Biomea Fusion, Inc.（纳斯达克股票代码：BMEA - 获取免费报告）在六月份看到了空头头寸的显著减少。截至 6 月 30 日，空头头寸总计为 7,840,000 股，较 6 月 15 日的 11,790,000 股减少了 33.5%。根据平均每日交易量为 1,320,000 股，目前的空头头寸比率为 5.9 天。该股约 28.2% 的股份被做空。</p>
<p>获取 <strong>Biomea Fusion</strong> 警报：</p>
<h2>Biomea Fusion 价格表现</h2>
<ul>
<li>这家小市值生物科技公司未来会有更大的涨幅吗？</li>
</ul>
<p>BMEA 在周五的交易时间内上涨了 0.33 美元，达到 5.29 美元。公司股票的成交量为 693,205 股，相比其平均成交量 1,301,165 股有所下降。该公司的 50 天移动平均价格为 8.03 美元，200 天移动平均价格为 12.70 美元。Biomea Fusion 的 52 周最低价为 3.61 美元，52 周最高价为 23.92 美元。</p>
<p>Biomea Fusion（纳斯达克股票代码：BMEA - 获取免费报告）上次公布财报是在 5 月 2 日星期四。该公司报告本季度每股亏损 1.09 美元，低于每股亏损 1.02 美元的共识预期 0.07 美元。作为一个整体，卖方分析师预计 Biomea Fusion 今年将发布-4.09 美元的每股收益。</p>
<h2>机构投资者对 Biomea Fusion 的看法</h2>
<p>大型投资者最近增加或减少了他们在该股票中的持股。Signaturefd LLC 在第四季度购入了 Biomea Fusion 的新股，价值约 36,000 美元。Grove Bank &amp; Trust 在第四季度购入了 Biomea Fusion 的新股，价值 56,000 美元。中国通用资产管理有限公司在第四季度将其对 Biomea Fusion 的持股增加了 348.5%。中国通用资产管理有限公司现在拥有该公司股票 4,131 股，价值 60,000 美元，较该期间增加了 3,210 股。Quest Partners LLC 在第四季度购入了 Biomea Fusion 的新股，价值 79,000 美元。最后，Centaurus Financial Inc.在第四季度购入了 Biomea Fusion 的新股，价值 102,000 美元。该股 96.72% 由对冲基金和其他机构投资者持有。</p>
<h2>分析师的升级和降级</h2>
<p>一些分析师最近发布了关于该公司的报告。HC Wainwright 重申了对 Biomea Fusion 的 “买入” 评级，并设定了 15.00 美元的价格目标，报告发布于 6 月 25 日星期二。Oppenheimer 将 Biomea Fusion 的价格目标从 70.00 美元降至 60.00 美元，并在 5 月 30 日星期四的研究报告中为该股票设定了 “表现优异” 的评级。花旗集团将 Biomea Fusion 的价格目标从 90.00 美元降至 45.00 美元，并在 6 月 7 日星期五的研究报告中为该公司设定了 “买入” 评级。Scotiabank 将 Biomea Fusion 的目标价从 41.00 美元降至 21.00 美元，并在 6 月 7 日星期五的报告中为该股票设定了 “行业表现优异” 的评级。最后，巴克莱将 Biomea Fusion 的评级从 “增持” 调降至 “持平”，并将该公司的价格目标从 30.00 美元降至 5.00 美元。三位投资分析师对该股票给予持有评级，五位分析师给予买入评级。根据 MarketBeat 的数据，Biomea Fusion 目前的平均评级为 “中等买入”，平均目标价为 28.25 美元。</p>
<p><strong>查看我们对 Biomea Fusion 的最新分析</strong></p>
<h2>关于 Biomea Fusion（获取免费报告）</h2>
<p>Biomea Fusion, Inc 是一家临床阶段的生物制药公司，专注于发现和开发共价小分子药物，用于治疗患有遗传性肿瘤和代谢性疾病的患者。其主要产品候选药物是 BMF-219，一种用于治疗液体和实体肿瘤以及 2 型糖尿病患者的 menin 共价抑制剂。</p>
<h2>推荐故事</h2>
<ul>
<li>我们比 Biomea Fusion 更喜欢的五只股票</li>
<li>CD 计算器：定期存款计算器</li>
<li>MarketBeat 周评 - 7/8 - 7/12</li>
<li>为什么要投资高股息股票？</li>
<li>为什么这家银行股可能接近周期底部</li>
<li>投资汽车股</li>
<li>前三大饮料股：夏季收益揭示关键趋势</li>
</ul>
<p>_此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前经 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</p>
<p>→ 不要说我没有警告过你...（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzM2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzM2"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Biomea Fusion？</h2>
<p>在考虑购买 Biomea Fusion 之前，您可能希望听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉他们的客户在更广泛市场注意之前现在购买的股票...而 Biomea Fusion 不在名单上。</p>
<p>尽管 Biomea Fusion 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

BMEA

<p>Biomea Fusion, Inc. (纳斯达克股票代码：BMEA) 在六月份经历了空头头寸的显著减少，股价下跌了 33.5%。目前的偿付日比率为 5.9 天。该公司的股价一直在波动，曾达到 52 周最高价$23.92，最低价为$3.61。分析师对该股票发出了不同的评级，平均评级为"中等买入"。Biomea Fusion 专注于开发针对遗传定义的癌症和代谢性疾病的共价小分子药物</p>

<p>Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) saw a significant decrease in short interest during the month of June. As of June 30th, there was short interest totalling 7,840,000 shares, a decrease of 33.5% from the June 15th total of 11,790,000 shares. Based on an average daily trading volume, of 1,320,000 shares, the short-interest ratio is currently 5.9 days. Approximately 28.2% of the shares of the stock are short sold.</p>
<div class="lb-trans"><p>Biomea Fusion, Inc.（纳斯达克股票代码：BMEA - 获取免费报告）在六月份看到了空头头寸的显著减少。截至 6 月 30 日，空头头寸总计为 7,840,000 股，较 6 月 15 日的 11,790,000 股减少了 33.5%。根据平均每日交易量为 1,320,000 股，目前的空头头寸比率为 5.9 天。该股约 28.2% 的股份被做空。</p>
</div><p>Get <strong>Biomea Fusion</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Biomea Fusion</strong> 警报：</p>
</div><h2>Biomea Fusion Price Performance</h2>
<ul>
<li>Are (More) Big Gains Ahead for This Small Cap Biotech Stock?</li>
</ul>
<div class="lb-trans"><h2>Biomea Fusion 价格表现</h2>
<ul>
<li>这家小市值生物科技公司未来会有更大的涨幅吗？</li>
</ul>
</div><p>BMEA traded up $0.33 during trading hours on Friday, reaching $5.29. 693,205 shares of the company's stock traded hands, compared to its average volume of 1,301,165. The firm has a 50-day moving average price of $8.03 and a 200 day moving average price of $12.70. Biomea Fusion has a 52-week low of $3.61 and a 52-week high of $23.92.</p>
<div class="lb-trans"><p>BMEA 在周五的交易时间内上涨了 0.33 美元，达到 5.29 美元。公司股票的成交量为 693,205 股，相比其平均成交量 1,301,165 股有所下降。该公司的 50 天移动平均价格为 8.03 美元，200 天移动平均价格为 12.70 美元。Biomea Fusion 的 52 周最低价为 3.61 美元，52 周最高价为 23.92 美元。</p>
</div><p>Biomea Fusion (NASDAQ:BMEA - Get Free Report) last released its earnings results on Thursday, May 2nd. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.07). As a group, sell-side analysts anticipate that Biomea Fusion will post -4.09 EPS for the current year.</p>
<div class="lb-trans"><p>Biomea Fusion（纳斯达克股票代码：BMEA - 获取免费报告）上次公布财报是在 5 月 2 日星期四。该公司报告本季度每股亏损 1.09 美元，低于每股亏损 1.02 美元的共识预期 0.07 美元。作为一个整体，卖方分析师预计 Biomea Fusion 今年将发布-4.09 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Biomea Fusion</h2>
<div class="lb-trans"><h2>机构投资者对 Biomea Fusion 的看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC bought a new stake in shares of Biomea Fusion during the fourth quarter valued at approximately $36,000. Grove Bank &amp; Trust bought a new stake in Biomea Fusion during the 4th quarter valued at $56,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Biomea Fusion by 348.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,131 shares of the company's stock worth $60,000 after buying an additional 3,210 shares during the period. Quest Partners LLC bought a new position in shares of Biomea Fusion during the 4th quarter worth $79,000. Finally, Centaurus Financial Inc. purchased a new position in shares of Biomea Fusion during the fourth quarter valued at $102,000. 96.72% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了他们在该股票中的持股。Signaturefd LLC 在第四季度购入了 Biomea Fusion 的新股，价值约 36,000 美元。Grove Bank &amp; Trust 在第四季度购入了 Biomea Fusion 的新股，价值 56,000 美元。中国通用资产管理有限公司在第四季度将其对 Biomea Fusion 的持股增加了 348.5%。中国通用资产管理有限公司现在拥有该公司股票 4,131 股，价值 60,000 美元，较该期间增加了 3,210 股。Quest Partners LLC 在第四季度购入了 Biomea Fusion 的新股，价值 79,000 美元。最后，Centaurus Financial Inc.在第四季度购入了 Biomea Fusion 的新股，价值 102,000 美元。该股 96.72% 由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和降级</h2>
</div><p>Several analysts have recently issued reports on the company. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $15.00 price objective on shares of Biomea Fusion in a report on Tuesday, June 25th. Oppenheimer decreased their price target on shares of Biomea Fusion from $70.00 to $60.00 and set an &#34;outperform&#34; rating on the stock in a research note on Thursday, May 30th. Citigroup dropped their price objective on shares of Biomea Fusion from $90.00 to $45.00 and set a &#34;buy&#34; rating for the company in a research note on Friday, June 7th. Scotiabank reduced their target price on shares of Biomea Fusion from $41.00 to $21.00 and set a &#34;sector outperform&#34; rating on the stock in a report on Friday, June 7th. Finally, Barclays downgraded shares of Biomea Fusion from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and lowered their price target for the company from $30.00 to $5.00 in a report on Friday, June 7th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Biomea Fusion currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $28.25.</p>
<div class="lb-trans"><p>一些分析师最近发布了关于该公司的报告。HC Wainwright 重申了对 Biomea Fusion 的 “买入” 评级，并设定了 15.00 美元的价格目标，报告发布于 6 月 25 日星期二。Oppenheimer 将 Biomea Fusion 的价格目标从 70.00 美元降至 60.00 美元，并在 5 月 30 日星期四的研究报告中为该股票设定了 “表现优异” 的评级。花旗集团将 Biomea Fusion 的价格目标从 90.00 美元降至 45.00 美元，并在 6 月 7 日星期五的研究报告中为该公司设定了 “买入” 评级。Scotiabank 将 Biomea Fusion 的目标价从 41.00 美元降至 21.00 美元，并在 6 月 7 日星期五的报告中为该股票设定了 “行业表现优异” 的评级。最后，巴克莱将 Biomea Fusion 的评级从 “增持” 调降至 “持平”，并将该公司的价格目标从 30.00 美元降至 5.00 美元。三位投资分析师对该股票给予持有评级，五位分析师给予买入评级。根据 MarketBeat 的数据，Biomea Fusion 目前的平均评级为 “中等买入”，平均目标价为 28.25 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Biomea Fusion</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Biomea Fusion 的最新分析</strong></p>
</div><h2>About Biomea Fusion (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Biomea Fusion（获取免费报告）</h2>
</div><p>Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.</p>
<div class="lb-trans"><p>Biomea Fusion, Inc 是一家临床阶段的生物制药公司，专注于发现和开发共价小分子药物，用于治疗患有遗传性肿瘤和代谢性疾病的患者。其主要产品候选药物是 BMF-219，一种用于治疗液体和实体肿瘤以及 2 型糖尿病患者的 menin 共价抑制剂。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Biomea Fusion</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>MarketBeat Week in Review – 7/8 - 7/12</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>Why This Banking Stock Might Be Nearing the Bottom of Its Cycle</li>
<li>Investing In Automotive Stocks</li>
<li>Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>我们比 Biomea Fusion 更喜欢的五只股票</li>
<li>CD 计算器：定期存款计算器</li>
<li>MarketBeat 周评 - 7/8 - 7/12</li>
<li>为什么要投资高股息股票？</li>
<li>为什么这家银行股可能接近周期底部</li>
<li>投资汽车股</li>
<li>前三大饮料股：夏季收益揭示关键趋势</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p>_此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前经 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</p>
</div><p>→ Don’t say I didn’t warn you… (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 不要说我没有警告过你...（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzM2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8736&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Biomea Fusion right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Biomea Fusion？</h2>
</div><p>Before you consider Biomea Fusion, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Biomea Fusion 之前，您可能希望听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biomea Fusion wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉他们的客户在更广泛市场注意之前现在购买的股票...而 Biomea Fusion 不在名单上。</p>
</div><p>While Biomea Fusion currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Biomea Fusion 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Biomea Fusion, Inc.（纳斯达克：BMEA）空头头寸显著减少